Inactive Instrument

Other languages Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Real-time Estimate Cboe Europe Other stock markets 10:13:21 2024-04-30 am EDT			5-day change	1st Jan Change
6.35 ^CHF	+164.58%		+0.42%	+3.91%

Apr. 24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
Apr. 17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Bourse Zurich: retour dans le rouge, Roche plombe l'indice	Apr. 24
Les ventes de Kuros s'envolent	Apr. 24
Kuros mit erneut starkem Umsatz- und Ergebnissprung im ersten Quartal	Apr. 24
Kuros Biosciences Posts Higher Q1 Product Sales	Apr. 24
Kuros Biosciences AG Approves Board of Director and Committee Changes	Apr. 17
Bourse Zurich: le SMI poursuit sa progression, nouveau plus haut de l'année	Mar. 13
Bourse Zurich: les indices passent l'épaule en fin de matinée	Mar. 13
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	Mar. 13
Kuros toujours dans le rouge en 2023 malgré des recettes plus que doublées	Mar. 13
Kuros hat nach Umsatzsprung den Verlust verringert	Mar. 13
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
Bourse Zurich: dans le rouge avant la Fed, Novartis pèse sur le SMI	Jan. 31
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use	Jan. 31
Kuros: nouvelles autorisations pour Magnetos aux USA et en Nouvelle-Zélande	Jan. 31
Kuros erhält weitere Zulassung für MagnetOs in den USA und Neuseeland	Jan. 31
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	Jan. 31
Kuros stellt neue Daten vor und erhält zwei weitere FDA-Zulassungen	Jan. 04
Kuros obtient deux nouvelles autorisations de la FDA et avance sur Magnetos	Jan. 04
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04
Aktien Schweiz nach Weihnachtspause etwas leichter	Dec. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Kuros Biosciences AG Swiss Exchange

Equities

CH0325814116

Other languages

Filters